TransCode Therapeutics, Inc. (NASDAQ:RNAZ) Short Interest Update

TransCode Therapeutics, Inc. (NASDAQ:RNAZ) saw a large decline in short interest in the month of March. As of March 15th, there was short interest totalling 339,800 shares, a decline of 37.2% from the February 28th total of 540,900 shares. Based on an average trading volume of 6,040,000 shares, the days-to-cover ratio is currently 0.1 days. Approximately 54.3% of the shares of the company are short sold.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of TransCode Therapeutics in a report on Thursday, March 13th.

TransCode Therapeutics Stock Down 5.8 %

TransCode Therapeutics stock traded down $0.03 during trading hours on Friday, hitting $0.49. 22,887,058 shares of the company traded hands, compared to its average volume of 1,742,585. The firm’s 50-day simple moving average is $5.01 and its two-hundred day simple moving average is $217.34. TransCode Therapeutics has a 1-year low of $0.49 and a 1-year high of $66.33.

About TransCode Therapeutics

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.